| 8.99 6.68 (289.18%) | 05-04 11:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.31 |
1-year : | 14.37 |
| Resists | First : | 10.53 |
Second : | 12.31 |
| Pivot price | 2.85 |
|||
| Supports | First : | 5.2 |
Second : | 1.89 |
| MAs | MA(5) : | 3.48 |
MA(20) : | 2.69 |
| MA(100) : | 4.19 |
MA(250) : | 7.09  |
|
| MACD | MACD : | 0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.1 |
D(3) : | 42.1 |
| RSI | RSI(14): 90.8 |
|||
| 52-week | High : | 34.79 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CNSP ] has closed above the upper band by 43.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 227% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.39 | 2.39 - 2.4 |
| Low: | 2.24 - 2.26 | 2.26 - 2.27 |
| Close: | 2.29 - 2.31 | 2.31 - 2.33 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Mon, 04 May 2026
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Fundraise - Blockonomi
Mon, 04 May 2026
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Funding Round - Blockonomi
Mon, 04 May 2026
Why CNS Pharmaceuticals (CNSP) Stock Is Up 215% Today - CoinCentral
Mon, 04 May 2026
Dow Falls Over 150 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Mon, 04 May 2026
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot - Benzinga
Mon, 04 May 2026
CNSP Stock Volatility Spikes As Traders Watch Key Levels - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 19 (%) |
| Shares Short | 58 (K) |
| Shares Short P.Month | 37 (K) |
| EPS | -35.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.4 % |
| Return on Equity (ttm) | -296.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -19.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 1.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|